Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.45 |
| ▸ | LPL | P06858 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718768 | 0.85 | LIPG (0.52) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL15092555 | 0.84 | LIPG (0.49) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL15092257 | 0.83 | LIPG (0.48) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2562199 | 0.83 | LIPG (0.48) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27635300 | 0.81 | F2 (0.46) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4880111 | 0.79 | CA12 (0.45) | CA1 | |
| SCHEMBL1872003 | 0.78 | ALDH1A1 (0.35) | CA1CA2 | |
| SCHEMBL7700107 | 0.78 | AOC3 (0.43) | — | |
| SCHEMBL15092531 | 0.78 | LIPG (0.42) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL12170334 | 0.76 | AAK1 (0.45) | F11F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
| US-6984756-B2 | Process for preparing biphenyl compounds | ELI LILLY AND COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1294683-B1 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1294683-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090055-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | F11 858/4885F2 798/4885PRSS1 260/4885 |
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | F11 858/4885F2 798/4885PRSS1 260/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | F11 858/4885F2 798/4885PRSS1 260/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | F11 3865/4885F2 3117/4885PRSS1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.